{"product_id":"omer-vrio-analysis","title":"Omeros Corporation (OMER): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eDiscover the true engine behind Omeros Corporation (OMER)'s market position with this sharp VRIO Analysis. We dissect its core assets against the crucial tests of Value, Rarity, Inimitability, and Organization to reveal precisely where its sustainable competitive advantage lies - or where critical gaps exist. Dive in now to see the distilled summary of what truly makes this business formidable and what it must address next.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOmeros Corporation (OMER) - VRIO Analysis: 1. Narsoplimab (MASP-2 Inhibitor) Clinical\/Regulatory Standing\n\u003c\/h2\u003e\n\n\u003cp\u003eYou are looking at Omeros Corporation's Narsoplimab, which is sitting right on the edge of a potential first-in-class approval for transplant-associated thrombotic microangiopathy (TA-TMA). Honestly, this is the make-or-break asset for the company right now, and the market is holding its breath for the FDA's decision.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Potential First-in-Class Approval and Market Opportunity\u003c\/h3\u003e\n\u003cp\u003eThe value proposition here is clear: a life-saving therapy for a condition with a high mortality rate and no current approved treatments. Narsoplimab targets MASP-2, the effector enzyme of the lectin pathway of complement. The clinical data package is compelling; pivotal trials showed a 61% complete response rate in TA-TMA patients, along with a threefold improvement in overall survival versus historical controls. The addressable market is tied to the roughly 30,000+ allogeneic hematopoietic stem cell transplants (HSCT) performed annually in the U.S. and Europe, with TA-TMA incidence estimated between 8-15% of those cases. The FDA accepted the Biologics License Application (BLA) resubmission in May 2025, assigning a target action date in late September 2025.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Unique Clinical Data Package\u003c\/h3\u003e\n\u003cp\u003eWhat makes this rare is the specific data set supporting the BLA resubmission. The primary analysis demonstrated statistically significant superiority in overall survival (a hazard ratio of 0.32 with a p-value less than 0.00001) when comparing the 28 patients in the pivotal trial to an external control registry. Furthermore, data from the global expanded access program (EAP) bolsters this, showing consistent safety and efficacy across over 130 treated patients. This specific combination of efficacy data, especially against a well-matched external control, is unique to Omeros Corporation's development path.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Biological Target and Trial Execution Hurdles\u003c\/h3\u003e\n\u003cp\u003eImitability is high in the sense that competitors are definitely targeting the complement pathway, but replicating the exact clinical execution and data package for TA-TMA is difficult to do quickly. Narsoplimab’s mechanism - inhibiting MASP-2 while preserving the classical complement pathway - offers a differentiation point from other complement inhibitors. The Orphan Drug designations in the U.S. (7 years) and EU (10 years) create a regulatory moat, even if the science itself is eventually replicated. Still, a competitor with deep pockets could theoretically pursue a similar target, though the time lag is significant.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Successful Regulatory and Financial Maneuvers\u003c\/h3\u003e\n\u003cp\u003eOmeros Corporation has shown organizational focus by successfully navigating the FDA's feedback and resubmitting the BLA in March 2025. They also prepared the Marketing Authorization Application (MAA) for the European Medicines Agency (EMA) for submission later in the quarter following the BLA resubmission. Financially, they strengthened the balance sheet in Q3 2025, receiving $20.3 million in net proceeds from a direct offering priced at a 14% premium and another $9.0 million from an ATM program. The Q3 2025 cash burn was $22.0 million, leaving them with $36.1 million in cash and short-term investments as of September 30, 2025. This demonstrates a focused effort to fund the path to potential commercialization.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary, Hinged on Regulatory Outcome\u003c\/h3\u003e\n\u003cp\u003eThe competitive advantage is currently Temporary. It hinges entirely on the FDA's late September 2025 decision and the subsequent market uptake. If approved, the orphan exclusivity provides a strong, albeit temporary, shield against direct competition in this niche. If the FDA denies approval or requests further data, the advantage evaporates instantly, leaving the company with a net loss of $30.9 million in Q3 2025 and a cash position that requires careful management.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on where Narsoplimab stands based on the VRIO framework:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eKey Supporting Data\/Metric (2025 Fiscal)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e61%\u003c\/strong\u003e complete response rate in pivotal trials\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eUnique survival data (HR 0.32, p \u0026lt; 0.00001) supporting BLA\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eMedium\/High Cost\u003c\/td\u003e\n    \u003ctd\u003eCompetitors target the complement pathway; Orphan Exclusivity provides a moat\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eSuccessful BLA resubmission (Class 2) with $36.1 million cash on hand as of 9\/30\/2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n    \u003ctd\u003eDependent on FDA decision by late September 2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the risk associated with the EMA review, which is expected to conclude by mid-2026. Also, the company's overall financial health, with a Q3 2025 net loss of $30.9 million, means successful commercialization infrastructure build-out is critical.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTarget Population: 8-15% incidence in 30,000+ annual HSCTs.\u003c\/li\u003e\n  \u003cli\u003eFinancing Strength: Raised $20.3 million net in Q3 2025.\u003c\/li\u003e\n  \u003cli\u003eCash Burn: $22.0 million in Q3 2025 (operating).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOmeros Corporation (OMER) - VRIO Analysis: 2. Zaltenibart Out-licensing to Novo Nordisk\n\u003c\/h2\u003e\n\n\u003cp\u003eThe closing of the asset purchase and license agreement with Novo Nordisk for zaltenibart occurred on \u003cstrong\u003eDecember 1, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe value component is quantified by the immediate and potential future cash flows derived from the transaction.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Component\u003c\/th\u003e\n\u003cth\u003eAmount (USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Cash Payment at Closing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$240.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront and Near-Term Milestones Total\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$340.0 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Milestones (Including Development\/Commercial)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$2.1 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe deal structure also includes tiered royalties on net sales of commercialized products.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe rarity is evidenced by the scale of the financial commitment for a late-stage asset, validating the MASP-3 science.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal potential consideration reaching up to \u003cstrong\u003e$2.1 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUpfront cash payment of \u003cstrong\u003e$240.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe imitable aspect relates to the underlying science, while the specific deal terms are unique to the negotiation.\u003c\/p\u003e\n\u003cp\u003eOmeros retains rights to its preclinical MASP-3 small-molecule program, including the ability to develop and commercialize small-molecule MASP-3 inhibitors with limited restrictions on indications.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization is demonstrated by immediate financial restructuring actions taken upon closing.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTransaction closed on \u003cstrong\u003eDecember 1, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePrepayment of the entire \u003cstrong\u003e$67.1 million\u003c\/strong\u003e principal amount outstanding under the senior secured term loan, along with premium, interest, and expenses.\u003c\/li\u003e\n\u003cli\u003eResulted in the termination of the senior secured credit agreement and the release of the \u003cstrong\u003e$25.0 million\u003c\/strong\u003e minimum liquidity covenant.\u003c\/li\u003e\n\u003cli\u003eExpected to fund more than \u003cstrong\u003e12 months\u003c\/strong\u003e of operations, including the anticipated U.S. launch of narsoplimab.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is derived from the immediate capital infusion.\u003c\/p\u003e\n\u003cp\u003eThe remaining proceeds are expected to be sufficient to repay the remaining \u003cstrong\u003e$17.1 million\u003c\/strong\u003e principal balance on its 2026 Convertible Notes.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOmeros Corporation (OMER) - VRIO Analysis: 3. Proprietary Complement Pathway Technology Platform\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Deep, specialized knowledge in inhibiting complement components like MASP-2 (narsoplimab) and MASP-3 (zaltenibart), providing a foundation for multiple pipeline assets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many firms target complement, but Omeros has demonstrated success with two distinct mechanisms (lectin and alternative pathways).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate to High; the core scientific understanding and proprietary molecules are protected by IP, but the general pathway is well-studied.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the company is clearly prioritizing MASP-2\/3, but other programs like OMS1029 show platform breadth.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, provided the core intellectual property around the specific inhibitors remains strong and defensible.\u003c\/p\u003e\n\n\u003cp\u003eThe platform's value is evidenced by clinical efficacy data and significant partnership potential:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNarsoplimab in TA-TMA demonstrated a statistically significant overall survival superiority with a Hazard Ratio of 0.32 (95% CI: 0.23 to 0.44) and a p-value less than 0.00001 compared to an external control registry.\u003c\/li\u003e\n\u003cli\u003eNarsoplimab achieved a 61% response rate and 68% 100-day survival in the pivotal trial, representing an approximately three-fold improvement over untreated cohorts.\u003c\/li\u003e\n\u003cli\u003eZaltenibart Phase 3 PNH development involves 120 clinical investigative sites across 30 countries.\u003c\/li\u003e\n\u003cli\u003eThe PNH market size is reported at $3.8 billion in 2023, projected to exceed $11.7 billion by 2034.\u003c\/li\u003e\n\u003cli\u003eThe agreement for zaltenibart grants Omeros eligibility for up to a total of $2.1 billion in milestones plus tiered royalties, including $340 million in upfront and near-term payments.\u003c\/li\u003e\n\u003cli\u003eOMER reported a net loss of $32.2 million for Q3 2024 and $31.4 million for Q4 2024.\u003c\/li\u003e\n\u003cli\u003eCash and short-term investments were $123.2 million as of September 30, 2024, decreasing to $28.7 million by June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eOMER earned $9.3 million in OMIDRIA royalties in Q3 2024 on $31.0 million in U.S. net sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eTarget Pathway\u003c\/th\u003e\n\u003cth\u003eMechanism\u003c\/th\u003e\n\u003cth\u003eLatest Clinical Status\u003c\/th\u003e\n\u003cth\u003eValue Driver\/Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNarsoplimab (OMS721)\u003c\/td\u003e\n\u003ctd\u003eLectin Pathway\u003c\/td\u003e\n\u003ctd\u003eMASP-2 Inhibitor\u003c\/td\u003e\n\u003ctd\u003eBLA resubmitted (March 2025) for TA-TMA.\u003c\/td\u003e\n\u003ctd\u003eOverall Survival HR of 0.32 in TA-TMA pivotal trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZaltenibart (OMS906)\u003c\/td\u003e\n\u003ctd\u003eAlternative Pathway\u003c\/td\u003e\n\u003ctd\u003eMASP-3 Inhibitor\u003c\/td\u003e\n\u003ctd\u003ePhase 3 PNH enrollment underway; BLA data expected Q4 2026.\u003c\/td\u003e\n\u003ctd\u003ePotential global deal value up to $2.1 billion plus royalties.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOMS1029\u003c\/td\u003e\n\u003ctd\u003eLectin Pathway\u003c\/td\u003e\n\u003ctd\u003eLong-acting MASP-2 Inhibitor\u003c\/td\u003e\n\u003ctd\u003eSuccessfully completed Phase 1 studies.\u003c\/td\u003e\n\u003ctd\u003eSecond-generation platform breadth; expected once-monthly to once-quarterly dosing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eOmeros Corporation (OMER) - VRIO Analysis: 4. OMIDRIA Royalty Stream\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A non-dilutive, recurring revenue stream from Rayner Surgical Inc.'s U.S. net sales, providing consistent, albeit fluctuating, cash flow.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOMER earned $8.6 million in OMIDRIA royalties on Rayner's U.S. net sales of $28.6 million for Q2 2025.\u003c\/li\u003e\n\u003cli\u003eOMER earned $9.2 million in OMIDRIA royalties on Rayner's U.S. net sales of $30.5 million for Q3 2025.\u003c\/li\u003e\n\u003cli\u003eThe U.S. royalty stream is remitted to DRI Health Acquisition LP through an escrow agent until 2031.\u003c\/li\u003e\n\u003cli\u003eThe original sale of OMIDRIA to Rayner occurred in December 2021.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; post-approval product royalties are common, but the specific terms and the asset itself are unique to Omeros.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe royalty structure involves two monetization agreements with DRI, the second of which provided OMER an additional $115 million for the entire 30 percent U.S. royalty stream through 2031.\u003c\/li\u003e\n\u003cli\u003eOMER is also eligible for two milestone payments from DRI, each up to $27.5 million, payable in January 2026 and January 2028.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the stream is based on existing contracts and past commercialization success, which cannot be easily duplicated.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe stream is governed by the Asset Purchase Agreement with Rayner and subsequent agreements with DRI dated September 30, 2022, and an amendment in 2024.\u003c\/li\u003e\n\u003cli\u003eThe initial royalty rate on OMIDRIA net revenues in Q2 2022 was 50 percent.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; they are actively managing this asset, though the focus has clearly shifted to the pipeline post-deal.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe U.S. royalty cash flow is currently directed to service obligations related to the DRI monetization transactions.\u003c\/li\u003e\n\u003cli\u003eOMER maintained $36.1 million in cash and short-term investments as of September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the royalty stream is finite and dependent on the underlying product's market life and contract terms.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe U.S. royalty stream is contracted to end in 2031.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOMIDRIA Royalty Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOMIDRIA Royalty Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRayner U.S. Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$28.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Royalty Stream End Date\u003c\/td\u003e\n\u003ctd\u003e2031\u003c\/td\u003e\n\u003ctd\u003eContractual Term\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Monetization Proceeds (from DRI)\u003c\/td\u003e\n\u003ctd\u003e$125 million\u003c\/td\u003e\n\u003ctd\u003eSeptember 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdditional Monetization Payment (from DRI)\u003c\/td\u003e\n\u003ctd\u003e$115 million\u003c\/td\u003e\n\u003ctd\u003eAmended Agreement (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Short-Term Investments\u003c\/td\u003e\n\u003ctd\u003e$36.1 million\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eOmeros Corporation (OMER) - VRIO Analysis: 5. Oncology Platform (OncotoX\/T-CAT)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Diversifies risk away from complement focus, offering potential first-in-class therapeutics in oncology (e.g., AML) and for multidrug-resistant organisms (T-CAT).\u003c\/p\u003e\n\u003cp\u003eThe U.S. sees over \u003cstrong\u003e20,000\u003c\/strong\u003e new AML diagnoses annually. The estimated AML market is projected to exceed \u003cstrong\u003e$6 billion\u003c\/strong\u003e by \u003cstrong\u003e2030\u003c\/strong\u003e. The T-CAT platform initial focus is on multidrug-resistant organisms (MDROs).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; the combination of signaling-driven immunomodulators, oncotoxins, and T-cell tech is a distinct approach.\u003c\/p\u003e\n\u003cp\u003eThe OncotoX-AML therapeutic has demonstrated superior efficacy to current AML standard of care treatments in both in vivo and in vitro models with human cell lines. OncotoX-AML shows broad application across AML regardless of genetic mutation, including \u003cstrong\u003eTP53\u003c\/strong\u003e, \u003cstrong\u003eNPM1\u003c\/strong\u003e, \u003cstrong\u003eKMT2a\u003c\/strong\u003e, and \u003cstrong\u003eFLT3\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; preclinical data is common, but translating this complex platform into clinical success is a high barrier.\u003c\/p\u003e\n\u003cp\u003eThe estimated timeline for the OncotoX-AML therapeutic to enter the clinic is \u003cstrong\u003e18-24\u003c\/strong\u003e months.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Emerging; the April 2025 establishment of the Oncology Clinical Steering Committee shows intent to organize around this.\u003c\/p\u003e\n\u003cp\u003eThe Omeros Oncology Clinical Steering Committee for AML was established in \u003cstrong\u003eApril 2025\u003c\/strong\u003e. OMER's net loss for the third quarter ended \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, was \u003cstrong\u003e$30.9 million\u003c\/strong\u003e. Cash burn during the third quarter of \u003cstrong\u003e2025\u003c\/strong\u003e, exclusive of financing proceeds, was \u003cstrong\u003e$22.0 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it's still early-stage, meaning the advantage is based on potential, not proven market position.\u003c\/p\u003e\n\u003cp\u003eCash and short-term investments available at \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, were \u003cstrong\u003e$36.1 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eSpecific Data Point\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Potential (AML)\u003c\/td\u003e\n\u003ctd\u003eProjected Market Size by 2030\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e$6 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Penetration Context\u003c\/td\u003e\n\u003ctd\u003eU.S. Annual AML Diagnoses\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e20,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical Efficacy\u003c\/td\u003e\n\u003ctd\u003eMutations Targeted in AML\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eTP53\u003c\/strong\u003e, \u003cstrong\u003eNPM1\u003c\/strong\u003e, \u003cstrong\u003eKMT2a\u003c\/strong\u003e, \u003cstrong\u003eFLT3\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganizational Milestone\u003c\/td\u003e\n\u003ctd\u003eOncology Clinical Steering Committee Establishment Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eApril 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment Timeline\u003c\/td\u003e\n\u003ctd\u003eEstimated Time to Clinic Entry (OncotoX-AML)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e18-24\u003c\/strong\u003e months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Health (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eCash and Short-Term Investments (Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$36.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003eOncotoX-AML has shown superior efficacy in animal models compared to current standard of care treatments.\u003c\/li\u003e\n\u003cli\u003eThe T-CAT platform is designed for broad applicability against diverse microbial species, with initial focus on multidrug-resistant organisms (MDROs).\u003c\/li\u003e\n\u003cli\u003eThe OncotoX program for AML consists of proprietary engineered molecules that are about half the size of an antibody.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOmeros Corporation (OMER) - VRIO Analysis: 6. Strengthened Balance Sheet Post-Novo Deal\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Elimination of debt obligations under the Credit Agreement, including a $67.1 million term loan principal repayment, and a cash balance bolstered by the $240.0 million upfront payment, providing operational flexibility.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare for a company of this size to so decisively clean up its balance sheet in late 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a specific financial transaction that has already occurred.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management executed the repayment immediately upon closing the asset sale on \u003cstrong\u003eNovember 25, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; while it provides a runway through \u003cstrong\u003e2027\u003c\/strong\u003e, capital will eventually be depleted without further success.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKey Balance Sheet Changes Post-Closing:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRepayment of the entire outstanding senior secured term loan principal of \u003cstrong\u003e$67.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTermination of the Credit Agreement and elimination of the \u003cstrong\u003e$25.0 million\u003c\/strong\u003e minimum liquidity covenant.\u003c\/li\u003e\n\u003cli\u003eExpected repayment of the remaining \u003cstrong\u003e$17.1 million\u003c\/strong\u003e principal balance on 2026 Convertible Notes at or prior to maturity.\u003c\/li\u003e\n\u003cli\u003eCash balance increased by the \u003cstrong\u003e$240.0 million\u003c\/strong\u003e upfront payment received.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount (USD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment Received\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$240.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront + Near-Term Milestones\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$340.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Deal Value\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$2.1 billion\u003c\/strong\u003e plus tiered royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSenior Secured Term Loan Repaid\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$67.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2026 Convertible Notes Principal Remaining (Expected to be repaid)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Short-Term Investments (June 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$28.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe transaction is structured to provide cash runway through \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOmeros Corporation (OMER) - VRIO Analysis: 7. Third-Party Manufacturing \u0026amp; Supply Chain Agreements\n\u003c\/h2\u003e\n\u003cp\u003eSecured, cGMP-compliant manufacturing capacity with established partners like Lonza Biologics and Vetter Pharma for narsoplimab. Omeros paid an \u003cstrong\u003e$18.4 million\u003c\/strong\u003e charge related to the delivery of narsoplimab drug substance, the manufacturing of which commenced in October 2023, as reported in their Q3 2024 financial results. Omeros does not own or operate internal manufacturing facilities capable of producing sufficient quantities under current Good Manufacturing Practices (“cGMP”) for commercial use.\u003c\/p\u003e\n\u003cp\u003eLow; established biopharma companies commonly rely on Contract Manufacturing Organizations (CMOs).\u003c\/p\u003e\n\u003cp\u003eLow; these are established contractual relationships, such as the master services agreement with Lonza Biologics entered into in July 2019 for commercial production.\u003c\/p\u003e\n\u003cp\u003eHigh; these agreements were crucial for supporting the Biologics License Application (BLA) submission, which was resubmitted to the FDA in March 2025, with an expected FDA action target date in September 2025.\u003c\/p\u003e\n\u003cp\u003eNone; this is a necessary operational requirement, not a source of advantage.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Fact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eSecured Capacity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$18.4 million\u003c\/strong\u003e charge paid for narsoplimab drug substance delivery (manufacturing commenced Oct 2023).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eReliance on external CMOs is standard industry practice.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eLong-term agreement with Lonza established in \u003cstrong\u003eJuly 2019\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eAgreements supported BLA resubmission in \u003cstrong\u003eMarch 2025\u003c\/strong\u003e with target action date of \u003cstrong\u003eSeptember 2025\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003ctd\u003eNecessary operational function for commercial readiness.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAgreements and Supply Chain Details:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMaster services agreement with Lonza Biologics Tuas Pte. Ltd. (“Lonza”) for commercial production of narsoplimab entered in \u003cstrong\u003eJuly 2019\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUtilization of a third-party vendor for labeling and final packaging of narsoplimab finished goods.\u003c\/li\u003e\n\u003cli\u003eObligation to purchase a minimum number of narsoplimab batches annually beginning on a specified anniversary of the first commercial sale in the U.S. or EU.\u003c\/li\u003e\n\u003cli\u003eLonza reported sales of \u003cstrong\u003eCHF 5.5 billion\u003c\/strong\u003e in 2018 with a CORE EBITDA of \u003cstrong\u003eCHF 1.5 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOmeros Corporation (OMER) - VRIO Analysis: 8. OMS527 Program Funding Status\n\u003c\/h2\u003e\n\u003cp\u003e\nOMS527 is a clinical-stage asset for cocaine use disorder that is fully funded by the National Institute on Drug Abuse (NIDA).\n\u003c\/p\u003e\n\u003cp\u003e\nRarity: Rare to have a late-stage asset with external, non-dilutive funding covering development costs.\n\u003c\/p\u003e\n\u003cp\u003e\nImitability: Low; the funding source and stage are specific to this program.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: High; the external funding de-risks the development spend for Omeros shareholders.\n\u003c\/p\u003e\n\u003cp\u003e\nCompetitive Advantage: Temporary; the advantage is in the cost structure, not necessarily market exclusivity.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFunding Source\u003c\/th\u003e\n\u003cth\u003eProgram Component\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003ePeriod\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIDA\u003c\/td\u003e\n\u003ctd\u003eClinical Development (Phase 1b)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.02 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUpcoming Year (April 1, 2025 through March 31, 2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIDA\u003c\/td\u003e\n\u003ctd\u003ePreclinical Studies and Clinical Study Support\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.69 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAwarded over three years, starting April 7, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOmeros (Claimed from NIDA Grant)\u003c\/td\u003e\n\u003ctd\u003eFunding Received to Date (as of Q2 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOf a previous total grant commitment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nAdditional statistical and financial data points related to the OMS527 program:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe current NIDA grant funds the Phase 1b clinical trial in patients with CUD to assess OMS527 safety and efficacy.\u003c\/li\u003e\n\u003cli\u003eInitial data readout from the Phase 1b trial is expected in the \u003cstrong\u003efourth quarter of 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOMS527 has successfully completed Phase 1 single-ascending- and multiple-ascending-dose clinical trials in healthy subjects.\u003c\/li\u003e\n\u003cli\u003eThe societal costs associated with substance use disorder in the United States in 2022 were estimated in excess of \u003cstrong\u003e$1 trillion\u003c\/strong\u003e annually.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOmeros Corporation (OMER) - VRIO Analysis: 9. Management's Focused Capital Allocation Strategy\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to pivot resources from paused programs to prioritize narsoplimab commercialization and debt reduction, as seen in Q1 2025 decisions.\u003c\/p\u003e\n\u003cp\u003eIn Q1 2025, Omeros elected to temporarily suspend or pause certain activities and programs to prioritize the allocation of capital to the development of commercial infrastructure and capacities needed for the successful launch of narsoplimab, assuming approval by the FDA. Total operating expenses for Q1 2025 were \\$35.0 million, a decrease from \\$39.0 million in Q1 2024. The wind down of the IgA nephropathy clinical program contributed to this decrease. The company's cash and short-term investments at March 31, 2025, were \\$52.4 million. Strategic financial maneuvers in Q1 2025 included reducing short-term debt repayment obligations from approximately \\$118 million to approximately \\$17 million following an exchange agreement on the 2026 Convertible Notes, which reduced the outstanding principal balance to approximately \\$17.1 million.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many firms struggle to make hard choices, but Omeros demonstrated decisive action in 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; strong leadership is hard to copy, but strategic pivots are common in biotech.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the leadership team is clearly directing capital toward the most imminent value driver (narsoplimab) and balance sheet repair.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe FDA accepted the resubmitted Biologics License Application (BLA) for narsoplimab in TA-TMA.\u003c\/li\u003e\n\u003cli\u003eThe company is prioritizing investment in the commercial infrastructure for narsoplimab.\u003c\/li\u003e\n\u003cli\u003eThe expanded access program for narsoplimab has been suspended to conserve capital, except for currently treated patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this advantage lasts only as long as the current leadership team maintains this disciplined focus.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e The Asset Purchase and License Agreement (APLA) with Novo Nordisk for Zaltenibart (OMS906), announced October 15, 2025, is expected to close in Q4 2025, providing an upfront cash payment of \\$240.0 million. This cash, combined with cash on hand (which was \\$36.1 million at September 30, 2025), is expected to fund significant debt repayment and operations.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePro-Forma Cash Flow Statement (Hypothetical, Post-Closing of Zaltenibart Transaction)\u003c\/th\u003e\n\u003cth\u003eAmount (Millions USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Short-Term Investments (Starting Point, based on Q3 2025 balance)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$36.1\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment from Novo Nordisk (Zaltenibart APLA)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$240.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepayment of Senior Secured Term Loan (Principal, Premium, Interest, Expenses)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e(\\$67.1)\u003c\/strong\u003e (Outstanding Principal Amount)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepayment of 2026 Convertible Notes (Principal)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e(\\$17.1)\u003c\/strong\u003e (Remaining Principal Balance)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eNet Cash from Financing Activities\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$155.8\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePro-Forma Cash Balance (Post-Financing\/Debt Repayment)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$191.9\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Post-Closing Operations Funding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;12 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe expected use of the \\$240.0 million upfront payment includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFunding the repayment at closing of all outstanding obligations under the senior secured credit agreement, including \\$67.1 million in outstanding term loan principal, a related prepayment premium, accrued and unpaid interest, and expenses.\u003c\/li\u003e\n\u003cli\u003eAllowing for repayment at or prior to maturity in February 2026 of the \\$17.1 million remaining principal balance of the 2026 convertible notes.\u003c\/li\u003e\n\u003cli\u003eProviding capital for more than 12 months of post-closing operations, including the anticipated U.S. launch of narsoplimab for TA-TMA.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516223316117,"sku":"omer-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/omer-vrio-analysis.png?v=1740201824","url":"https:\/\/dcf-model.com\/fr\/products\/omer-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}